Meso
Aftermath
Archived
Renouveau du biotech : activité de M&A et performance du marché
Activité en déclin — le récit perd de sa pertinence.
Score
0,3
Vélocité
▲ 0,0
Articles
13
Sources
2
Chronologie des sentiments
Performance Sectorielle
Performance des actions
Chronologie des événements
Articles Liés
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
Yahoo Finance
·
Mar 21, 2026
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
Nasdaq
·
Mar 20, 2026
My Top 3 Drug Stocks for March 2026
Nasdaq
·
Mar 20, 2026
Why biotech is back: IBT portfolio manager’s view
Yahoo Finance
·
Mar 20, 2026